Is elamipretide FDA-approved? What Forzinity approval does—and does not—cover

01

The approved product and indication are narrow

FDA approved Forzinity, whose active ingredient is elamipretide, on September 19, 2025. The prescribing information states that it is indicated to improve muscle strength in adult and pediatric patients with Barth syndrome who weigh at least 30 kilograms. Barth syndrome is a rare inherited mitochondrial disorder; the approval is not a general authorization for fatigue, exercise performance, healthy aging, weight management, or nonspecific “mitochondrial support.”

Approval is product-specific. A consumer should match the brand name, active ingredient, labeled indication, manufacturer, dosage form, and current prescribing information. A clinic page that mentions elamipretide, a vial labeled SS-31, a compounded preparation, and FDA-approved Forzinity are not interchangeable records merely because the names may be connected in scientific literature or marketing.

02

What accelerated approval means here

FDA used the accelerated approval pathway, which can permit earlier approval for a serious condition based on a measure considered reasonably likely to predict clinical benefit. Forzinity's label says the indication was approved based on improvement in knee extensor muscle strength, an intermediate clinical endpoint. The label also says continued approval may depend on verification and description of clinical benefit in a confirmatory trial.

Accelerated approval is still FDA approval; it should not be described as merely experimental. It also is not the same as a conventional approval supported by direct confirmation of the final patient benefit. FDA's current accelerated-approval table lists Forzinity as ongoing and identifies a randomized, double-blind, placebo-controlled postmarketing study intended to verify the predicted benefit.

03

The evidence base is important—and limited

FDA's Drug Trials Snapshot reports that the pivotal program enrolled 12 patients with genetically confirmed Barth syndrome at one U.S. site. All were male, all were at least 12 years old, and nearly all were White. Such a small and demographically narrow dataset limits how confidently results can be generalized beyond the studied population.

The Snapshot says Forzinity was not superior to placebo on the randomized study's primary endpoints: the six-minute walk test and a fatigue score. Increases in knee extensor strength were observed during the longer open-label extension rather than the randomized portion. Open-label extensions can provide useful long-term information, but they lack a concurrent blinded control and are more vulnerable to selection, expectation, and time-related effects.

04

Safety information belongs with the benefit claim

The current prescribing information identifies injection-site reactions as the most common adverse reactions. It also includes a contraindication for serious hypersensitivity to elamipretide or an excipient, and warns that serious allergic reactions requiring emergency intervention have been reported. The label includes additional population-specific cautions and should be read as a whole by the prescribing clinician and patient.

A directory article cannot decide whether the labeled product is appropriate for an individual or translate its label into a personal regimen. Consumers researching a provider should ask who diagnoses and manages the rare condition, how the prescription is obtained, which pharmacy dispenses the approved product, and how adverse reactions and follow-up are handled.

05

Why SS-31 and wellness offers need separate verification

Elamipretide has also been called SS-31 in research contexts. That synonym can create a misleading shortcut: a seller may point to Forzinity's approval while offering a different product, source, formulation, or use. The existence of an approved drug does not authenticate an online vial, authorize a compounded copy, or extend the approved indication to every mitochondrial claim.

Ask for the exact National Drug Code if the provider says it is dispensing the approved product, then match the product label and manufacturer to the current FDA record. If the provider describes the item as compounded, investigational, or sourced for research, record that classification accurately. Do not let an abbreviation, chemical synonym, certificate, or study citation substitute for product identity.

• →Exact brand and nonproprietary name
• →Manufacturer and dispensing pharmacy
• →FDA-approved, off-label, compounded, or investigational classification
• →Labeled versus marketed purpose
• →Current label and source date

06

A practical provider-research workflow

Start with the FDA label, Drug Trials Snapshot, and accelerated-approval status page. Compare those records with the clinic's exact statement. A careful provider should distinguish the labeled Barth syndrome use from any off-label discussion and should not imply that approval proves benefits for other mitochondrial or wellness goals.

Verify the treating clinician's license for the patient's location, the pharmacy identity, and the package received. Preserve screenshots and dates because labels, trial status, and provider offerings can change. Treatment decisions should be made with an appropriately licensed clinician familiar with the patient and the current prescribing information.